On February 23, 2009, GTx, Inc. issued a press release announcing that it has initiated a Phase I clinical trial for GTx-758, an oral luteinizing hormone (LH) inhibitor to treat men with advanced prostate cancer, a copy of which is furnished as Exhibit 99.1 to this Current Report. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758 using a single ascending dose, double blind, placebo controlled design in healthy male volunteers.

(c) Exhibits

       Exhibit
       Number    Description
       99.1      Press Release issued by GTx, Inc. dated February 23, 2009